文献速递临床试验与 GCP基础与转化研究

拉瑞唑肽治疗儿童新冠感染后多系统炎症综合征:病毒刺突抗原清除加快与恢复改善

Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide.
PubMed 文献 · Sci Transl Med · 2025-07-30

这项2a期随机双盲安慰剂对照试验在12例中位年龄5.7岁的儿童多系统炎症综合征(MISC)患者中测试紧密连接蛋白拮抗剂拉瑞唑肽,每日四次、持续3周,随访24周。未报告拉瑞唑肽相关不良事件;血SARS-CoV-2刺突蛋白抗原浓度与干扰素-γ(P=0.004)、白细胞介素-6(P<0.0001)及PedsQL胃肠道症状评分(P=0.003)相关。拉瑞唑肽组胃肠道症状缓解、刺突抗原清除及恢复正常活动均更快。

要点

  • 拉瑞唑肽治疗MISC患儿未报告相关不良事件。
  • 血刺突抗原浓度与干扰素-γ(P=0.004)、白细胞介素-6(P<0.0001)及胃肠道症状评分(P=0.003)相关。
  • 拉瑞唑肽组胃肠道症状缓解、刺突抗原清除和恢复正常活动更快。

核心结论

  • 作者认为拉瑞唑肽用于MISC患儿辅助治疗可能安全,并可能改善症状缓解。

研究设计与样本

  • 2a期随机双盲安慰剂对照临床试验纳入12例中位年龄5.7岁的MISC患儿,急性MISC住院期间入组,辅助拉瑞唑肽每日四次治疗3周,安全性随访24周。

主要发现

  • 未报告拉瑞唑肽相关不良事件。
  • 血SARS-CoV-2刺突蛋白抗原浓度与干扰素-γ(P=0.004)、白细胞介素-6(P<0.0001)及PedsQL胃肠道症状评分(P=0.003)相关。
  • 拉瑞唑肽组胃肠道症状缓解更快、刺突抗原清除更快、恢复正常活动更快。

临床怎么用

  • 作者认为拉瑞唑肽作为MISC辅助治疗可能安全并可能改善症状缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multisystem inflammatory syndrome (MIS) is a severe disease that occurs weeks to months after acute infection with SARS-CoV-2, often occurring in children (MISC). Symptoms include high fever, rash, nausea, diarrhea, and abdominal pain. Children with MISC can develop cardiovascular injury including ventricular failure, coronary artery aneurysms, or shock. Current treatment strategies for these postacute sequelae of COVID-19 primarily target the hyperinflammatory response. However, a potential role for viral spike protein translocated via zonulin-mediated trafficking from gastrointestinal reservoirs of SARS-CoV-2 into the circulation has been suggested. Here, we report results from a phase 2a randomized, double-blind, placebo-controlled clinical trial testing the zonulin antagonist larazotide in 12 children with MISC with a median age of 5.7 years. Children were enrolled during hospitalization for acute MISC and were treated with adjuvant larazotide therapy four times daily for 3 weeks. Patients were monitored for 24 weeks for safety follow-up. No larazotide-related adverse events were reported. The concentration of SARS-CoV-2 spike protein antigen in blood samples correlated with inflammatory markers, including interferon-γ (IFN-γ) (P = 0.004) and interleukin-6 (IL-6) (P < 0.0001), and with gastrointestinal symptoms as assessed by the PedsQL GI symptom score (P = 0.003). Children treated with larazotide displayed faster resolution of gastrointestinal symptoms, faster clearance of spike antigen, and a faster return to usual activities. Our findings suggest that larazotide treatment may be safe in children and may improve resolution of symptoms when used as an adjuvant therapy for MISC.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Yonker LM, Kane AS, Swank Z, et al. Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide. Sci Transl Med. 2025. PMID: 40737433. doi:10.1126/scitranslmed.adu4284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。